On September 21st 2009, reMYND received in the Flemish Parliament 'the 1st Award for Company with an exceptional relevance to society' out of the hands of the Flemish minister-president Kris Peeters.
reMYND receives award for Company with an exceptional relevance to society
reMYND awarded by the Michael J. Fox Foundation
reMYND is one of the nine biotech and pharmaceutical companies that have been awarded by the Michael J. Fox Foundation for Parkinson's Research in July 2009.
reMYND signs license with BioPredic
reMYND signs a license with BioPredic for commercialization RadarScreen as a diagnostic kit for experimental use in Europe and Japan. Visit the BioPredic website
reMYND receives a grant of almost 1 million EUR from IWT
reMYND receives a grant of almost 1 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT). Visit the IWT website
reMYND's Lead Alzheimer drug demonstrates neuroprotection
reMYND's Lead Alzheimer drug demonstrates neuroprotection in 2 transgenic animal models of TAU and Amyloid bèta pathology.